Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Nancy Bradish Myers

Contributor

Washington, DC

Nancy Bradish Myers is a Washington-based attorney with expertise in health care policy development, regulatory strategy, government relations and political analysis. She is the President of Catalyst Healthcare Consulting, Inc. a seasoned health care consulting firm that provides clients with a range of services from regulatory intelligence, strategic policy analysis and development assistance, to regulatory coaching in order allow biopharmaceutical, medical device companies, trade associations, investors, and patient advocacy organizations become more effective, efficient achieving their objectives. Ms. Myers is very goal oriented and enjoys helping clients strategically expand their sphere of influence in the health policy and regulatory space.

Set Alert for Articles By Nancy Bradish Myers

Latest From Nancy Bradish Myers

Scientific Wave Pushes CBER Into Brighter Light

What are US regulators doing to prepare for adequate review of the upcoming wave of gene therapy applications, and what other actions could CBER take to ensure it is able to facilitate the expected onslaught of breakthroughs in this field? Consultant Nancy Bradish Myers weighs in.

FDA Biologics

How A Rapid, Well-Messaged US FDA Offense Is Driving Spectators To Their Feet And Twitter Accounts

Consultant Nancy Bradish Myers examines why US FDA seems to be accomplishing so much under Commissioner Gottlieb’s leadership and how this could inform future leadership selections.

FDA Leadership

How a Rapid and Well-Messaged US FDA Offense Is Driving Spectators to Their Feet and Twitter Accounts

Consultant examines why FDA seems to be accomplishing so much under FDA Commissioner Gottlieb’s leadership and how this could inform future leadership selections.

FDA Leadership

UFA Creep: Time to Apply the Brake?

FDA’s user fee programs continue to proliferate. The new resources are great, but FDA and its stakeholders need to think carefully before going even further down this road.

BioPharmaceutical Regulation
See All
UsernamePublicRestriction

Register